Dr. Chung on Sequencing Chemotherapy Regimens in Metastatic Pancreatic Cancer

Vincent Chung, MD
Published: Wednesday, Jan 30, 2019



Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

When it comes to choosing a chemotherapy regimen for patients, much of the decision comes down to toxicity, says Chung. For that reason, Chung recommends starting these patients on gemcitabine and nab-paclitaxel (Abraxane). Although nab-paclitaxel causes a lot of neuropathy, it tends to resolve over time, he adds. If a patient progresses on that regimen, they can start on second-line nanoliposomal irinotecan and 5-fluorouracil, which offers good disease control.

As opposed to nab-paclitaxel, the neuropathy seen with the use of oxaliplatin is more permanent. Therefore, oxaliplatin is typically reserved for later lines of therapy, explains Chung. For a patient with a very good performance status who is given modified FOLFIRINOX, Chung advises dropping the oxaliplatin as neuropathy becomes more evident.
SELECTED
LANGUAGE


Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, Director Phase I Program, City of Hope, discusses sequencing chemotherapy regimens in patients with metastatic pancreatic cancer.

When it comes to choosing a chemotherapy regimen for patients, much of the decision comes down to toxicity, says Chung. For that reason, Chung recommends starting these patients on gemcitabine and nab-paclitaxel (Abraxane). Although nab-paclitaxel causes a lot of neuropathy, it tends to resolve over time, he adds. If a patient progresses on that regimen, they can start on second-line nanoliposomal irinotecan and 5-fluorouracil, which offers good disease control.

As opposed to nab-paclitaxel, the neuropathy seen with the use of oxaliplatin is more permanent. Therefore, oxaliplatin is typically reserved for later lines of therapy, explains Chung. For a patient with a very good performance status who is given modified FOLFIRINOX, Chung advises dropping the oxaliplatin as neuropathy becomes more evident.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x